Digest Network Come funziona
Network
/
Società
Ca
Non verificato

Capsida Biotherapeutics

Di cosa scriviamo

BiotecnologiaIgiene alimentareIndustriaMedicina - VarieSalute

5 comunicati stampa

Guarda tutti i comunicati
11/06/2025
Igiene alimentare
Salute
Biotecnologia
Farmaceutica
Medicina - Varie
Industria
Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson’s Disease Associated With GBA Mutations
Fonte
Capsida Biotherapeutics
Emittente
Business Wire
1.00
0
29/05/2025
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Capsida Receives FDA Fast Track Designation for Its Potential First-in-Class IV-Administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
Fonte
Capsida Biotherapeutics
Emittente
Business Wire
1.00
0
14/05/2025
Industria
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
Fonte
Capsida Biotherapeutics
Emittente
Business Wire
1.00
0
12/05/2025
Biotecnologia
Igiene alimentare
Salute
Medicina - Varie
Capsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
Fonte
Capsida Biotherapeutics
Emittente
Business Wire
1.00
0
28/04/2025
Web e Social Network
Eventi
Salute
Biotecnologia
Scienza
Sanità
Capsida to Present Progress Updates at the ASGCT Annual Meeting, Including NHP GLP Toxicology Study Results for its Potential First-in-Class STXBP1 Developmental and Epileptic Encephalopathy Program (CAP-002 STXBP1-DEE)
Fonte
Capsida Biotherapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0